The Oz healthcare landscape appears to be on the cusp of a major shift with the likely release of Retatrutide, also known as ElmodaStat or NovoPen. This new injectable medication, a dual GIP and GLP-1 receptor agonist, https://australianpeptidestore.co/bpc-157-10mg-research-peptide-australian-peptide-store/